See more : Rana Gruber ASA (RANA.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Merck & Co., Inc. (MRK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merck & Co., Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- M&T 1997, a.s. (KLIKY.PR) Income Statement Analysis – Financial Results
- METAWATER Co., Ltd. (9551.T) Income Statement Analysis – Financial Results
- Finnovate Acquisition Corp. (FNVT) Income Statement Analysis – Financial Results
- Accrete Inc. (4395.T) Income Statement Analysis – Financial Results
- CC Japan Income & Growth Trust plc (CCJI.L) Income Statement Analysis – Financial Results
Merck & Co., Inc. (MRK)
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.12B | 59.28B | 48.70B | 41.52B | 46.84B | 42.29B | 40.12B | 39.81B | 39.50B | 42.24B | 44.03B | 47.27B | 48.05B | 45.99B | 27.43B | 23.85B | 24.20B | 22.64B | 22.01B | 22.94B | 22.49B | 51.79B | 47.72B | 40.36B | 32.71B | 26.90B | 23.64B | 19.83B | 16.68B | 14.97B | 10.50B | 9.66B | 8.60B | 7.67B | 6.55B | 5.94B | 5.06B | 4.13B | 3.55B |
| Cost of Revenue | 16.13B | 17.41B | 13.63B | 13.62B | 14.11B | 13.51B | 12.78B | 13.89B | 14.93B | 16.77B | 16.95B | 16.45B | 16.87B | 18.40B | 9.02B | 5.58B | 6.14B | 6.00B | 5.15B | 4.96B | 4.32B | 33.05B | 28.98B | 21.17B | 16.71B | 13.17B | 10.95B | 8.59B | 6.79B | 5.28B | 2.11B | 1.77B | 1.67B | 1.52B | 1.33B | 1.32B | 1.23B | 1.14B | 1.09B |
| Gross Profit | 43.99B | 41.87B | 35.08B | 27.90B | 32.73B | 28.79B | 27.35B | 25.92B | 24.56B | 25.47B | 27.08B | 30.82B | 31.18B | 27.59B | 18.41B | 18.27B | 18.06B | 16.63B | 16.86B | 17.98B | 18.17B | 18.74B | 18.74B | 19.20B | 16.01B | 13.72B | 12.68B | 11.24B | 9.89B | 9.69B | 8.39B | 7.89B | 6.93B | 6.15B | 5.22B | 4.62B | 3.83B | 2.98B | 2.46B |
| Gross Profit Ratio | 73.17% | 70.63% | 72.02% | 67.20% | 69.87% | 68.06% | 68.16% | 65.10% | 62.19% | 60.30% | 61.50% | 65.21% | 64.89% | 60.00% | 67.12% | 76.59% | 74.62% | 73.49% | 76.61% | 78.38% | 80.81% | 36.18% | 39.27% | 47.56% | 48.93% | 51.02% | 53.66% | 56.69% | 59.30% | 64.72% | 79.89% | 81.63% | 80.57% | 80.13% | 79.72% | 77.76% | 75.61% | 72.29% | 69.28% |
| Research & Development | 30.53B | 13.55B | 12.25B | 13.40B | 9.87B | 9.75B | 9.98B | 7.19B | 6.70B | 7.18B | 7.50B | 8.17B | 8.47B | 10.99B | 5.85B | 4.81B | 4.88B | 4.78B | 3.85B | 4.01B | 3.18B | 2.68B | 2.46B | 2.34B | 2.07B | 1.82B | 1.68B | 1.49B | 1.33B | 1.23B | 1.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.20B | 7.84B | 7.63B | 7.16B | 8.72B | 8.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.30B | 2.20B | 2.00B | 1.80B | 1.90B | 2.10B | 9.83B | 9.76B | 10.31B | 11.61B | 11.91B | 12.78B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.50B | 10.04B | 9.63B | 8.96B | 10.62B | 10.10B | 9.83B | 9.76B | 10.31B | 11.61B | 11.91B | 12.78B | 13.73B | 13.25B | 8.54B | 7.38B | 7.56B | 8.17B | 7.16B | 7.35B | 6.39B | 6.19B | 6.22B | 6.17B | 5.20B | 4.51B | 4.30B | 3.84B | 3.30B | 3.18B | 2.91B | 4.07B | 3.56B | 3.24B | 2.76B | 2.55B | 2.25B | 1.75B | 1.33B |
| Other Expenses | 0.00 | 960.00M | 468.00M | 469.00M | -139.00M | 849.00M | 304.00M | -357.00M | -72.00M | 12.00B | 12.00M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 40.91B | 23.59B | 21.88B | 22.35B | 20.49B | 19.85B | 19.81B | 16.96B | 17.02B | 18.79B | 19.41B | 20.94B | 22.20B | 24.24B | 14.39B | 12.18B | 12.44B | 12.95B | 11.00B | 11.36B | 9.71B | 9.07B | 9.01B | 10.11B | 8.41B | 7.35B | 7.02B | 6.26B | 5.49B | 5.28B | 4.50B | 4.40B | 3.82B | 3.50B | 2.99B | 2.75B | 2.46B | 1.94B | 1.62B |
| Cost & Expenses | 57.16B | 41.00B | 35.51B | 35.97B | 34.60B | 33.36B | 32.59B | 30.85B | 31.95B | 35.55B | 36.37B | 37.39B | 39.07B | 42.63B | 23.41B | 17.76B | 18.58B | 18.95B | 16.15B | 16.32B | 14.03B | 42.12B | 37.99B | 31.27B | 25.12B | 20.52B | 17.97B | 14.84B | 12.28B | 10.56B | 6.61B | 6.17B | 5.49B | 5.02B | 4.31B | 4.07B | 3.69B | 3.09B | 2.71B |
| Interest Income | 365.00M | 157.00M | 36.00M | 59.00M | 274.00M | 343.00M | 385.00M | 328.00M | 289.00M | 266.00M | 264.00M | 232.00M | 199.00M | 83.00M | 210.20M | 631.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.15B | 962.00M | 806.00M | 831.00M | 893.00M | 772.00M | 754.00M | 693.00M | 672.00M | 732.00M | 801.00M | 714.00M | 749.00M | 715.00M | 458.00M | 251.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.87B | 3.91B | 3.21B | 3.49B | 3.65B | 4.52B | 4.64B | 5.44B | 6.38B | 6.69B | 6.99B | 6.98B | 7.43B | 7.38B | 2.58B | 1.63B | 1.99B | 2.27B | 1.71B | 1.45B | 1.31B | 1.49B | 1.46B | 1.28B | 1.14B | 1.02B | 1.03B | 927.10M | 859.20M | 875.50M | 414.70M | 321.40M | 263.80M | 254.00M | 221.70M | 204.90M | 210.00M | 193.90M | 182.50M |
| EBITDA | 6.91B | 21.32B | 17.90B | 10.18B | 16.01B | 13.99B | 11.95B | 10.79B | 12.45B | 24.71B | 13.33B | 16.43B | 15.51B | 9.75B | 18.33B | 11.81B | 13.06B | 5.98B | 7.75B | 7.58B | 9.44B | 11.07B | 10.94B | 9.63B | 7.54B | 5.27B | 5.64B | 5.07B | 4.68B | 5.05B | 4.95B | 3.74B | 3.32B | 2.86B | 2.41B | 2.07B | 1.54B | 1.13B | 936.90M |
| EBITDA Ratio | 11.49% | 39.32% | 34.73% | 23.03% | 27.50% | 24.24% | 20.60% | 22.65% | 20.18% | 45.48% | 18.95% | 22.84% | 20.37% | 24.80% | -18.28% | 28.56% | 53.99% | 26.43% | 35.22% | 33.05% | 41.98% | 21.37% | 22.92% | 23.85% | 23.05% | 19.58% | 23.88% | 25.58% | 28.05% | 33.75% | 47.14% | 38.71% | 38.55% | 37.25% | 36.81% | 34.81% | 30.49% | 27.47% | 26.41% |
| Operating Income | 2.95B | 19.40B | 13.70B | 6.08B | 9.23B | 5.73B | 3.63B | 3.58B | 1.59B | 12.52B | 1.36B | 3.82B | 2.36B | 4.03B | -7.59B | 5.18B | 11.08B | 3.71B | 6.04B | 6.13B | 8.13B | 9.58B | 9.47B | 8.35B | 6.39B | 4.25B | 4.61B | 4.15B | 3.82B | 4.18B | 4.53B | 3.42B | 3.05B | 2.60B | 2.19B | 1.86B | 1.33B | 940.20M | 754.40M |
| Operating Income Ratio | 4.91% | 32.72% | 28.14% | 14.63% | 19.70% | 13.55% | 9.04% | 8.98% | 4.04% | 29.64% | 3.08% | 8.08% | 4.91% | 8.75% | -27.67% | 21.72% | 45.77% | 16.41% | 27.46% | 26.73% | 36.14% | 18.50% | 19.86% | 20.69% | 19.55% | 15.80% | 19.50% | 20.91% | 22.90% | 27.90% | 43.19% | 35.39% | 35.49% | 33.94% | 33.43% | 31.36% | 26.34% | 22.77% | 21.27% |
| Total Other Income/Expenses | -1.07B | -1.84B | 680.00M | 315.00M | 3.54B | -230.00M | -986.00M | 1.08B | -2.15B | 4.77B | -2.12B | -1.14B | -1.64B | -1.70B | 11.27B | 3.85B | -2.25B | 2.63B | 1.44B | 530.90M | 926.30M | 632.60M | 927.90M | 735.00M | 2.23B | 3.88B | 1.85B | 1.40B | 977.80M | 238.00M | -783.00M | 144.20M | 114.00M | 94.80M | 93.40M | 8.40M | 72.00M | 133.10M | 102.60M |
| Income Before Tax | 1.89B | 16.44B | 13.88B | 8.79B | 11.46B | 8.70B | 6.75B | 7.50B | 5.40B | 17.28B | 5.55B | 9.23B | 7.33B | 1.65B | 15.29B | 9.81B | 3.37B | 6.22B | 7.36B | 7.97B | 9.05B | 10.21B | 10.40B | 9.82B | 8.62B | 8.13B | 6.46B | 5.54B | 4.80B | 4.42B | 3.10B | 3.56B | 3.17B | 2.70B | 2.28B | 1.87B | 1.41B | 1.07B | 857.00M |
| Income Before Tax Ratio | 3.14% | 27.74% | 28.50% | 21.17% | 24.47% | 20.57% | 16.82% | 18.84% | 13.67% | 40.92% | 12.59% | 19.53% | 15.26% | 3.59% | 55.75% | 41.12% | 13.93% | 27.48% | 33.45% | 34.76% | 40.25% | 19.72% | 21.80% | 24.34% | 26.35% | 30.24% | 27.34% | 27.94% | 28.76% | 29.49% | 29.55% | 36.88% | 36.81% | 35.18% | 34.85% | 31.50% | 27.76% | 25.99% | 24.16% |
| Income Tax Expense | 1.51B | 1.92B | 1.52B | 1.71B | 1.69B | 2.51B | 4.16B | 1.79B | 942.00M | 5.35B | 1.03B | 2.44B | 942.00M | 671.00M | 2.27B | 2.00B | 95.30M | 1.79B | 2.73B | 2.16B | 2.46B | 3.06B | 3.12B | 3.00B | 2.73B | 2.88B | 1.85B | 1.66B | 1.46B | 1.42B | 936.50M | 1.12B | 1.05B | 917.60M | 787.60M | 664.20M | 498.80M | 397.60M | 317.10M |
| Net Income | 365.00M | 14.52B | 13.05B | 7.07B | 9.84B | 6.22B | 2.57B | 5.69B | 4.44B | 11.92B | 4.40B | 6.66B | 6.27B | 861.00M | 12.90B | 7.81B | 3.28B | 4.43B | 4.63B | 5.81B | 6.83B | 7.15B | 7.28B | 6.82B | 5.89B | 5.25B | 4.61B | 3.88B | 3.34B | 3.00B | 2.17B | 1.98B | 2.12B | 1.78B | 1.50B | 1.21B | 906.40M | 675.70M | 539.90M |
| Net Income Ratio | 0.61% | 24.49% | 26.79% | 17.02% | 21.01% | 14.71% | 6.40% | 14.30% | 11.25% | 28.22% | 10.00% | 14.09% | 13.05% | 1.87% | 47.04% | 32.74% | 13.54% | 19.59% | 21.04% | 25.34% | 30.38% | 13.80% | 15.26% | 16.90% | 18.01% | 19.51% | 19.52% | 19.57% | 19.99% | 20.02% | 20.63% | 20.54% | 24.66% | 23.22% | 22.83% | 20.32% | 17.91% | 16.37% | 15.22% |
| EPS | 0.14 | 5.73 | 5.16 | 2.79 | 3.84 | 2.40 | 0.95 | 2.07 | 1.60 | 4.20 | 1.50 | 2.20 | 2.06 | 0.28 | 4.15 | 3.65 | -1.04 | 2.04 | 2.11 | 2.63 | 2.97 | 3.17 | 3.18 | 2.96 | 2.51 | 2.21 | 1.92 | 1.60 | 1.35 | 1.19 | 0.94 | 1.06 | 0.92 | 0.76 | 0.63 | 0.51 | 0.37 | 0.27 | 0.21 |
| EPS Diluted | 0.14 | 5.71 | 5.14 | 2.78 | 3.82 | 2.32 | 0.93 | 2.04 | 1.56 | 4.07 | 1.47 | 2.16 | 2.02 | 0.28 | 4.15 | 3.63 | -1.04 | 2.03 | 2.10 | 2.62 | 2.97 | 3.14 | 3.14 | 2.90 | 2.45 | 2.15 | 1.87 | 1.56 | 1.32 | 1.18 | 0.93 | 1.05 | 0.91 | 0.76 | 0.63 | 0.51 | 0.37 | 0.27 | 0.21 |
| Weighted Avg Shares Out | 2.61B | 2.53B | 2.53B | 2.53B | 2.57B | 2.59B | 2.70B | 2.75B | 2.78B | 2.84B | 2.93B | 3.03B | 3.04B | 3.10B | 2.11B | 2.14B | 2.17B | 2.18B | 2.20B | 2.22B | 2.24B | 2.26B | 2.29B | 2.31B | 2.35B | 2.37B | 2.40B | 2.43B | 2.47B | 2.51B | 2.30B | 1.87B | 2.31B | 2.34B | 2.37B | 2.37B | 2.45B | 2.50B | 2.57B |
| Weighted Avg Shares Out (Dil) | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B | 2.68B | 2.75B | 2.79B | 2.84B | 2.93B | 3.00B | 3.08B | 3.09B | 3.12B | 2.27B | 2.14B | 2.19B | 2.19B | 2.20B | 2.23B | 2.25B | 2.28B | 2.32B | 2.35B | 2.40B | 2.44B | 2.47B | 2.49B | 2.54B | 2.55B | 2.33B | 1.89B | 2.33B | 2.34B | 2.37B | 2.37B | 2.45B | 2.50B | 2.57B |
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works.
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
These stocks have seen better days but investors shouldn't count them out in the long run.
Merck: An Undervalued Dividend Machine
Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the oncology drugs industry, which is expected to observe a 6.7% CAGR over...
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared to the consensus estimates of $16.5 billion and $1.50, respectively.
Merck to Participate in the UBS Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the UBS Global Healthcare Conference.
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These stocks near 52-week lows could be ready to rebound.
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors' attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.
Investing Groups Digest: Mag 7 In The Market Spotlight
Seeking Alpha's Investing Group leaders presented their earnings assessments from Mag 7 tech giants. Are investors missing hidden opportunities with BDCs, CEFs, mREITs, and preferreds? The case is made for breaking up Realty Income.
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
The Dow finished October down slightly. Should you buy any of these blue chips?
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night.
Source: https://incomestatements.info
Category: Stock Reports